ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article

Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats)

[version 1; peer review: 1 approved with reservations]
PUBLISHED 20 Feb 2023
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Cell & Molecular Biology gateway.

Abstract

Background: Spinal cord injury (SCI) is a damage to the spinal cord caused mainly by trauma resulting in major motor, sensory and autonomic dysfunctions. Its final neurological outcome is determined by both primary and secondary injury processes. A key component of secondary injury mechanisms after initial trauma is neuroinflammation. A neuroprotective compound, ACTH4-10Pro8-Gly9-Pro10 (ACTH4-10) also known as semax, has shown neuroprotective and anti-inflammatory properties. ACTH4-10 has also been actively used in the treatment of brain ischemia without serious complication reported. Here, we analyzed the effects of ACTH4-10 at regulating the inflammatory cascade in SCI by looking at anti-inflammatory cytokine (IL-4, IL-10 and IL-13) levels after acute SCI.
Method: We carried out laminectomies in male Sprague Dawley rats at the second thoracic vertebrae. After laminectomy, we exposed the myelum and created mild SCI models with 20-g, and severe SCI with 35-g aneurysm clips. ACTH4-10 was administered intranasally to the treatment group and 0.9% NaCl to the control group (placebo). Both groups were kept alive and terminated at 3 and 6 hours. The tissue sample preparations were fixed in formalin and examined for immunohistochemistry. Quantitative measurement of the cytokines was done in the posterior horn area with specific associated anti-monoclonal antibodies.
Results: Rats with mild SCI that were given ACTH4-10 showed greater anti-inflammatory levels at 3 hours post-compression but only IL-10 and IL-13 were elevated significantly at 6 hours. Rats with severe compression in ACTH4-10 group showed greater levels of IL-10, IL-13 at 3 hours and IL-4, IL-10 at 6 hours compared with the placebo group.
Conclusions: Administration of ACTH4-10Pro8-Gly9-Pro10 intranasal can increase anti-inflammatory cytokine expression in Sprague Dawley rat models with mild and severe SCI. Expression of anti-inflammatory cytokines was greater in mild compression and 3-hour termination. Further research is needed to determine the optimal dose and clinical outcome in vivo.

Keywords

Spinal Cord Injury, Anti inflammatory cytokine, Neuroprotector, Experimental, Laminectomy

Introduction

Spinal cord injury (SCI) is a pathological condition that is known to cause severe neurological deterioration resulting in physical dependency, morbidity, mortality and financial burden for decades.1 Even tough significant research has been conducted to develop effective treatments for SCI, until now none of these treatments has shown any meaningful effect to improve functional outcome after injury.2

Demographic data suggest that SCI mainly affects the male population with over 80% cases occurring in males between 25 to 45 year of age.3 Interestingly, not only do males have a higher incidence rate of SCI, but some studies have also shown males tend to have worse recovery rates compared with females.4 This phenomenon is thought to be caused by female sex hormone such as progesterone and estrogen, that have shown modest neuroprotective behaviour in brain injury.5

In general, pathophysiology of traumatic SCI comprises primary and secondary injury. The primary injury is caused by the initial traumatic event such as compression, distraction, laceration and transection; this kind of injury causes irreversible damage to the spinal cord. In contrast, secondary injury, including processes such as neuroinflammation, spinal cord ischemia, and cellular excitotoxicity which begin soon after the initial trauma, give a window of opportunity to prevent further damage of the spinal cord. Therefore, managing secondary injuries remains the main target for SCI treatment.6,7

Above all the potential threats from secondary SCI, neuroinflammation is thought to be the key component causing many local and systemic consequences. It is known that injury to the spinal cord initiates an inflammatory-mediated response that could alter the repair processes within the nervous system and cause more damage to the nerves. Therefore, managing inflammation is thought to be an important factor for optimizing the outcome of SCI.8

Inflammation response in the spinal cord begins after macrophages activation and recruitment at the site of injury; activation of these macrophages could work in different pathways promoting, but also inhibiting the inflammation. Macrophages initiate inflammation by releasing pro-inflammatory cytokines (IL-1, IL-6, IL-8, IFN-γ and TNF-α) and other chemical mediators. After three or four days, macrophages that initiate and maintain the inflammation will then be deactivated by anti-inflammatory cytokines (IL-4, IL-10, IL-13 and TGF-β) that are also mainly produced by macrophages. The way that macrophages could regulate the inflammatory process is through the activation and counterbalance of pro- and anti-inflammatory cytokines. This balance determines the net effect of the inflammatory response in SCI.9,10

ACTH4-10Pro8-Gly9-Pro10 is an adrenocorticotropic hormone analogue that is known to have an anti-inflammatory effect.11 It has also been used in many conditions such as stroke, traumatic brain injury and Alzheimer disease as a neuroprotective agent with no report of serious complications.12

This experimental study was intended to show the effect of ACTH4-10 administration on anti-inflammatory cytokine levels in the spinal cord after acute SCI.

Methods

In this study we used 12-week-old male Sprague Dawley rats weighing 250-300 g to reproduce homogenous sample for SCI models and eliminate confounding factor such as sex hormone. This animal study obtained ethical clearance by the Airlangga University animal care and use committee number 2.KE.094.07.2021 to ensure all effort was taken to reduce animal suffering. After randomization, 27 samples were divided into nine groups of three samples each. Laminectomy at the level of second thoracic vertebra was performed on all the samples. We took one group with the spinal cord left uninjured as a baseline control. The other samples became the treatment groups, in which SCI was performed by compressing the spine using an aneurysm clip in one minute with a clamping force of 20 g to reproduce mild SCI (four groups) and 35 g for severe SCI models (four groups).13 The laminectomy site was then closed with sutures and the Sprague Dawley rats were kept alive.

After closing the suture, all treatment groups were divided into two subgroups. Placebo control groups were given 0.9 % NaCl intranasally, while the positive treatment groups were given ACTH4-10Pro8-Gly9-Pro10 intranasally at a 300 mg/kg dose. Each group was divided again into two groups to be respectively terminated at 3 hours and 6 hours after compression. Myelum transection was performed at the level of injured myelum after the termination.

SCI myelum samples were fixed in 10% formalin and examined for IHC with specific monoclonal antibodies for each of IL-4, IL-10 and IL-13. Examination was done on the posterior horn of myelum to ensure homogenous sampling area in each group. Then anti-inflammatory cytokines were counted per 100 cells using associated anti-monoclonal antibodies and viewed with a light microscope at 1000× magnification. Cells with a brown colour in the cytoplasm showed positive expression of each anti-inflammatory cytokine.

The result of cytokine level measurements in each group are shown in a relative expression graph. Normality data analysis was performed using a Shapiro-Wilk test. Normally distributed data were analyzed with ANOVA while the data with non-normal distribution were analyzed using a Kruskal-Wallis test, followed by a non-parametric Mann-Whitney U test.

Results

We carried out an experimental study in 27 male Sprague Dawley rats weighing 250-300 g, we severed the spinal cords in the area of injury, then we fixed the specimen with formalin. The specimen was then cut into 4-6 μm-thick slices with rotatory microtome and mounted on glass slides before further staining as seen in Figure 1.

806503f3-2203-49f5-9cfb-85919a19ab38_figure1.gif

Figure 1. Myelum sample from control group (A), mild spinal cord injury (SCI, B), severe SCI (C).

After immunohistochemistry staining with each specific antibody we examined the posterior horn area and counted stained cell number per 100 cells with a light microscope at 1000× magnification. Positive cells appeared brown as seen in Figure 2.

806503f3-2203-49f5-9cfb-85919a19ab38_figure2.gif

Figure 2. Cells were counted to assess anti-inflammatory cytokine levels in SCI models.37

Immunoreacted neutrophil cytoplasm that stained brown after using monoclonal antibodies are shown. White arrows mark positive stained neutrophils for IL-4 (A), IL-10 (B) and IL-13 (C) in mild spinal cord injury (SCI) group.

Table 1 shows higher IL-4 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration that were terminated after three and six hours, compared to the placebo group.

Table 1. ANOVA study of IL-4 levels. SCI: spinal cord injury.

GroupIL-4 expression
MeanStandard deviationp
Control5.962.520.005*
Mild SCI NaCl 0.9% 3 hours6.293.40
Mild SCI NaCl 0.9% 6 hours5.612.45
Mild SCI ACTH4-10 3 hours10.391.67
Mild SCI ACTH4-10 6 hours8.051.62
Control5.752.200.001*
Severe SCI NaCl 0.9% 3 hours7.322.26
Severe SCI NaCl 0.9% 6 hours5.292.16
Severe SCI ACTH4-10 3 hours9.361.98
Severe SCI ACTH4-10 6 hours9.211.37

* p < 0.05.

Table 2 shows higher IL-10 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration and who were terminated after three and six hours compared to the placebo group.

Table 2. ANOVA study of IL-10 levels.

GroupIL-10 expression
MeanStandard deviationp
Control5.571.573<0.001*
Mild SCI NaCl 0.9% 3 hours6.861.848
Mild SCI NaCl 0.9% 6 hours4.711.741
Mild SCI ACTH4-10 3 hours14.642.893
Mild SCI ACTH4-10 6 hours11.461.350
Control5.361.587
Severe SCI NaCl 0.9% 3 hours7.072.344
Severe SCI NaCl 0.9% 6 hours5.711.629
Severe SCI ACTH4-10 3 hours13.253.086
Severe SCI ACTH4-10 6 hours9.542.138

* p < 0.05.

Table 3 shows higher IL-13 levels in both mild and severe SCI models with ACTH4-10Pro8-Gly9-Pro10 administration and who were terminates after three and six hours compared to the placebo group.

Table 3. ANOVA study of IL-13 level.

GroupIL-13 expression
MeanStandard deviationp
Control3.861.682<0.001*
Mild SCI NaCl 0.9% 3 hours7.862.445
Mild SCI NaCl 0.9% 6 hours6.252.046
Mild SCI ACTH4-10 3 hours13.361.676
Mild SCI ACTH4-10 6 hours11.573.313
Control4.501.893
Severe SCI NaCl 0.9% 3 hours5.791.410
Severe SCI NaCl 0.9% 6 hours5.681.718
Severe SCI ACTH4-10 3 hours10.183.570
Severe SCI ACTH4-10 6 hours9.001.893

* p < 0.05.

Using Shapiro-Wilk test, we found our data had a normal distribution; further statistical analysis was carried out with a post hoc study using the Tukey method (Tables 4-9).

Table 4. Post hoc study of IL-4 level in mild SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control5.962.52NaCl 0.9% 3 hours6.293.400.999
NaCl 0.9% 6 hours5.612.450.999
ACTH4-10 3 hours10.391.670.015*
ACTH4-10 6 hours8.051.620.510
NaCl 0.9% 3 hour6.293.40NaCl 0.9% 6 hours5.612.450.984
ACTH4-10 3 hours10.391.670.027*
ACTH4-10 6 hours8.051.620.663
NaCl 0.9% 6 hour5.612.45ACTH4-10 3 hours10.391.670.007*
ACTH4-10 6 hours8.051.620.353
ACTH4-10 3 hour10.391.67ACTH4-10 6 hours8.041.620.382

* p < 0.05.

Table 5. Post hoc study of IL-10 level in mild SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control5.571.573NaCl 0.9% 3 hours6.861.8480.734
NaCl 0.9% 6 hours4.711.7410.922
ACTH4-10 3 hours14.642.893<0.001*
ACTH4-10 6 hours11.461.350<0.001*
NaCl 0.9% 3 hour6.861.848NaCl 0.9% 6 hours4.711.7410.268
ACTH4-10 3 hours14.642.893<0.001*
ACTH4-10 6 hours11.461.350<0.001*
NaCl 0.9% 6 hour4.711.741ACTH4-10 3 hours14.642.893<0.001*
ACTH4-10 6 hours11.461.350<0.001*
ACTH4-10 3 hour14.642.893ACTH4-10 6 hours11.461.3500.036*

* p < 0.05.

Table 6. Post hoc study of IL-13 level in mild SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control3.861.682NaCl 0.9% 3 hours7.862.4450.023*
NaCl 0.9% 6 hours6.252.0460.322
ACTH4-10 3 hours13.361.676<0.001*
ACTH4-10 6 hours11.573.313<0.001*
NaCl 0.9% 3 hour7.862.445NaCl 0.9% 6 hours6.252.0460.694
ACTH4-10 3 hours13.361.6760.001*
ACTH4-10 6 hours11.573.3130.040*
NaCl 0.9% 6 hour6.252.046ACTH4-10 3 hours13.361.676<0.001*
ACTH4-10 6 hours11.573.3130.001*
ACTH4-10 3 hour13.361.676ACTH4-10 6 hours11.573.3130.605

* p < 0.05.

Table 7. Post hoc study of IL-4 level in severe SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control5.752.20NaCl 0.9% 3 hours7.322.260.600
NaCl 0.9% 6 hours5.292.160.993
ACTH4-10 3 hours9.361.980.018*
ACTH4-10 6 hours9.211.370.025*
NaCl 0.9% 3 hour7.322.26NaCl 0.9% 6 hours5.292.160.349
ACTH4-10 3 hours9.361.980.349
ACTH4-10 6 hours9.211.370.421
NaCl 0.9% 6 hour5.292.16ACTH4-10 3 hours9.361.980.006*
ACTH4-10 6 hours9.211.370.009*
ACTH4-10 3 hour9.361.98ACTH4-10 6 hours9.211.371.000

* p < 0.05.

Table 8. Post hoc study of IL-10 level in severe SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control5.361.587NaCl 0.9% 3 hours7.072.3440.607
NaCl 0.9% 6 hours5.711.6290.998
ACTH4-10 3 hours13.253.086<0.001*
ACTH4-10 6 hours9.542.1380.012
NaCl 0.9% 3 hour7.072.344NaCl 0.9% 6 hours5.711.6290.784
ACTH4-10 3 hours13.253.086<0.001*
ACTH4-10 6 hours9.542.1380.258
NaCl 0.9% 6 hour5.711.629ACTH4-10 3 hours13.253.086<0.001*
ACTH4-10 6 hours9.542.1380.024*
ACTH4-10 3 hour13.253.086ACTH4-10 6 hours9.542.1380.030*

* p < 0.05.

Table 9. Post hoc study of IL-13 level in severe SCI.

GroupMeanStandard deviationGroupMeanStandard deviationp
Control4.501.893NaCl 0.9% 3 hours5.791.4100.816
NaCl 0.9% 6 hours5.681.7180.858
ACTH4-10 3 hours10.183.570<0.001
ACTH4-10 6 hours9.001.8930.006*
NaCl 0.9% 3 hour5.791.410NaCl 0.9% 6 hours5.681.7181.000
ACTH4-10 3 hours10.183.5700.007*
ACTH4-10 6 hours9.001.8930.078
NaCl 0.9% 6 hour5.681.718ACTH4-10 3 hours10.183.5700.006*
ACTH4-10 6 hours9.001.8930.064
ACTH4-10 3 hour10.183.570ACTH4-10 6 hours9.001.8930.858

* p < 0.05.

Mean levels of IL4, IL-10 and IL-13 were higher in the mild SCI models group that was given ACTH4-10Pro8-Gly9-Pro10 for both three- and six-hour termination groups, compared with placebo. IL-14 levels in models given ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 10.39 and 8.05 respectively, and 6.29 and 5.61 respectively in the placebo group. IL-10 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 14.64 and 11.46 respectively, while in the placebo group they were 6.86 and 4.71 respectively. IL-13 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 13.36 and 11.57 respectively, and 7.86 and 6.25 respectively in the placebo group. Post hoc analysis with Tukey test showed significant differences in IL-4, IL-10 and IL-13 at three hours, and in IL-10 and IL-13 at six hours.

The results from severe SCI models that were given ACTH4-10Pro8-Gly9-Pro10 also showed higher mean IL-4, IL-10 and IL-13 levels compared with placebos in the three-hour and six-hour groups. IL-4 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 9.36 and 9.21 respectively, and 7.82 and 5.29 respectively in the placebo. IL-10 levels in ACTH4-10Pro8-Gly9-Pro10 at three and six hourswas 13.25 and 9.54 respectively, while in placebos they were 7.07 and 5.71, respectively. IL-13 levels in models administered ACTH4-10Pro8-Gly9-Pro10 at three and six hours were 10.18 and 9.00 respectively, while in placebo they were 5.79 and 5.68 respectively. Post hoc analysis with Tukey test showed significant differences in IL-10 and IL-13 levels at three hours, and in IL-4 and IL-10 at six hours. Overall, level of anti-inflammatory cytokines were higher in each treatment group compared with placebo; the levels were significantly higher in models with mild SCI and terminated three hours after injury.

Discussion

Inflammation following the primary spinal cord injury is known to cause further spinal cord damage, resulting in apoptosis of oligodendrocyte, demyelination and degradation of axons, and neuronal cell death. Many attempts were made to reduce this deleterious effect caused by inflammation after initial injury occurrs.14

Neuroinflammation following the primary injury is predominantly regulated by the balance of macrophage activation.15 In order to regulate this inflammation cascade, macrophages play a key role by releasing pro- or anti-inflammatory cytokine. Studies in SCI models have shown that some pro-inflammatory cytokines like TNF-α, IL-1, and IL-6 are found upregulated within an hour after injury, leading to further inflammatory response causing neuronal apoptosis.16 In contrast, anti-inflammatory cytokines that are capable of altering macrophage activity, such as IL-4, IL-131619 and IL-10 which can directly inhibiting other pro-inflammatory cytokines, are generally present at low levels after SCI.20,21

We realize sex hormone like estrogen and progesterone have some immunosuppressive profile in SCI22; to minimize this potentially confounding factor that might bias the outcome we only used male Sprague Dawley rats in this study. Our study found significantly higher IL-4, IL-10 and IL-13 levels in the mild SCI group that was terminated after three hours, and higher IL-10, IL-13 levels in the six-hour termination group that was given ACTH4-10. In the severe SCI group that were given ACTH4-10, we found higher IL-10, IL-13 levels in the group that was terminated after three hours, and higher IL-4 and IL-10 levels after six hours.

Compared with mild SCI, in the severe SCI group inflammation was more pronounced and abundant in pro-inflammatory cytokines. These pro-inflammatory cytokines in turn could suppress the release of anti-inflammatory cytokines. In addition, inflammation that occurs in SCI rat models is known to begin one hour after injury and reach its peak at six hours after injury.23 This may explain our finding that in the group with severe SCI and termination six hours after injury, anti-inflammatory cytokine expression ratio between the ACTH4-10Pro8- Gly9-Pro10 and placebo groups was not as high as in the mild SCI and three-hour group.

ACTH4-10Pro8-Gly9-Pro10 is an analogue of adrenocorticotropic hormone and is created from a fragment of ACTH(4–7) combined with C-terminal tripeptide Pro-Gly-Pro, which acts as a neuroprotective compound.24 Similar to its analogue, ACTH4-10Pro8-Gly9-Pro10 is said to bind at the melanocortin receptor promoting anti-inflammatory and neuroprotective effects.25 Activated melanocortin receptors could supress pro-inflammatory cytokine release and promote the anti-inflammatory cytokine release. Together, this condition could supress inflammation.26

Methylprednisolone sodium succinate (MP) became the most discussed treatment in the last three to four decades for reducing the deleterious effect caused by inflammation after initial injury occurs. The first study that was conducted in the early 1980s showed a promising potential neuroprotective effect of MP in reducing inflammation after acute SCI in a preclinical setting. This study has led many clinicians to do more extensive research (NASCIS I and II).27,28 This large-scale randomized control trial showed that there was a statistical improvement in neurological outcomes in the treatment group compared with the placebo if MP was administered within less than eight hours after initial injury.28,29 However, with an average increase of just five points in the American Spinal Injury Association (ASIA) impairment score compared with the placebo, this was said to not be clinically significant in the overall quality of life of the patient. Moreover, along with the limited overall improvement, a high dose of MP came with several complications, such as increased rate of infection along with gastrointestinal haemorrhages.30,31 Considering the limited benefit and potential morbidity or even life-threatening complications, in 2013 the American Association of Neurological Surgeon (AANS) ruled out MP administration from the current recommendations for managing patients with SCI.32,33

Our finding showing increased levels of anti-inflammatory cytokines in the treatment group complements previous studies that revealed ACTH4-10Pro8-Gly9-Pro10 could decrease pro-inflammatory cytokines in SCI rats model.34,35 Those studies might provide a fundamental basis showing ACTH4-10Pro8- Gly9-Pro10 could reduce inflammation and potentially prevent secondary injury in SCI. To date, ACTH4-10Pro8- Gly9-Pro10 has been used as a neuroprotective agent for stroke and Alzheimer patients with no report of serious complications. It has also been given through the intranasal route and has a rapid onset within minute, allowing this drug to be given early on after the initial injury. Finally, we see potential benefits from ACTH4-10Pro8- Gly9-Pro10 to reduce inflammation and its deleterious effect on secondary injury after SCI.

Conclusions

Administration of ACTH4-10Pro8-Gly9-Pro10 can increase anti-inflammatory cytokine levels in Sprague Dawley rat models with mild and severe SCI. Rats with mild compression that were terminate after three hours showed an increase in IL-4, IL-10 and IL-13; after six hours, only IL-10 and IL-13 were increased. Rats with severe compression that were terminate after three hours showed an increase in IL-10 and IL-13; after six hours, only IL-4, IL-10 were increased. Further studies are needed to determine the optimal dose and functional outcome in rats with SCI.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 20 Feb 2023
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Asadullah A, Bajamal AH, Parenrengi MA et al. Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats) [version 1; peer review: 1 approved with reservations]. F1000Research 2023, 12:194 (https://doi.org/10.12688/f1000research.127413.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 20 Feb 2023
Views
24
Cite
Reviewer Report 13 Mar 2023
Mawaddah Ar Rochmah, Department of Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia 
Approved with Reservations
VIEWS 24
This study explored the use of ACTH4-10Pro8-Gly9-Pro10 in the rat model of spinal cord injury (SCI). The study focused on the role of the above-mentioned agent in ameliorating neuroinflammation within the acute phase of the SCI by measuring the inflammatory ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Ar Rochmah M. Reviewer Report For: Effect of ACTH4-10Pro8-Gly9-Pro10 on anti-inflammatory cytokine (IL-4, IL-10, IL-13) expression in acute spinal cord injury models (male Sprague Dawley rats) [version 1; peer review: 1 approved with reservations]. F1000Research 2023, 12:194 (https://doi.org/10.5256/f1000research.139917.r164062)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 08 Oct 2024
    Asadullah Asadullah, Neurosurgery Residency Program, Airlangga University, Surabaya, 60132, Indonesia
    08 Oct 2024
    Author Response
    • Why was the ACTH4-10Pro8-Gly9-Pro10 intranasally at a 300 mg/kg dose chosen? Any previous study that suggested the dose? If any, please provide the reference and citation.
    >This is ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 08 Oct 2024
    Asadullah Asadullah, Neurosurgery Residency Program, Airlangga University, Surabaya, 60132, Indonesia
    08 Oct 2024
    Author Response
    • Why was the ACTH4-10Pro8-Gly9-Pro10 intranasally at a 300 mg/kg dose chosen? Any previous study that suggested the dose? If any, please provide the reference and citation.
    >This is ... Continue reading

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 20 Feb 2023
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.